Latest News

  • TapImmune Sponsors 26.2 With DONNA Marathon for Br...

      Events & Marathon to take place in Jacksonville, Florida on February 12-14, 2016   JACKSONVILLE, FLORIDA, February 10, 2016 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology...

    Read more

  • TapImmune: Proud Supporter of World Cancer Day, F...

    World Cancer Day is marked on February 4 to raise awareness of cancer and to encourage its prevention, detection, and treatment. World Cancer Day was founded by the Union for International Cancer...

    Read more

  • TapImmune Granted Fast Track Designation by U.S. F...

    TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer &...

    Read more

  • TapImmune Appoints Frederick G. Wasserman to its B...

    TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of...

    Read more

  • TapImmune to Present at Biotech Showcase 2016 in S...

    JACKSONVILLE, FLORIDA, January 7 , 2015 / TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and...

    Read more

  • TapImmune moves forward with new drugs...

    By Mark Basch, Contributing Writer TapImmune Inc. is a pharmaceutical research company that may never make a big splash in Jacksonville, as far as local employment and operations go.However, the...

    Read more

  • We Are Back!

    We regret that due to circumstances beyond our control our website was offline over the weekend and yesterday.    We are in the process of re-engineering and updating our website to better serve...

    Read more

  • Patrick Yeramian Multi-Epitope Vaccine Granted Orp...

    The orphan designation for TPIV 200 was based on findings from a phase I study, which were electronically published in conjunction with the 2015 ASCO Annual Meeting. In the study, treatment with the...

    Read more

  • TapImmune Presents New Data at San Antonio Breast ...

    JACKSONVILLE, Florida, December 10, 2015 Vaccination with TPIV 100 boosts T-cell immunity to HER2 in HER2+ Breast Cancer Patients Provides catalyst to start Phase II studies TapImmune, Inc. (TPIV), a...

    Read more

  • U.S. Food & Drug Administration Grants Orphan...

    Company preparing for Phase II ovarian cancer trial based on positive data in Mayo Clinic Phase I trial JACKSONVILLE, Florida, December 9, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), a...

    Read more

  • TapImmune to Present New Data at San Antonio Breas...

    TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer...

    Read more

  • TapImmune CEO, Glynn Wilson speaks with CBS 12R...

    Trials underway to test vaccine against several cancers Story by Lynda Figueredo/CBS12 For the first time ever, a Palm Beach County doctor is on the verge of one of the biggest medical breakthroughs...

    Read more

  • Immuno-Oncology Company, TapImmune Inc., Moves Cor...

    Clinical-Stage Developer of Vaccines for Cancer & Metastatic Disease moves into closer proximity to collaborators at Mayo Clinic in Jacksonville JACKSONVILLE, Florida, November 5, 2015...

    Read more

  • TapImmune to Present at Dawson James Small Cap Gro...

    JACKSONVILLE, Florida, October 13, 2015 /PRNewswire/ TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based...

    Read more

  • TapImmune to Present at Aegis Capital 2015 Growth ...

    JACKSONVILLE, Florida, October 7, 2015 /PRNewswire/ –   TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based...

    Read more

  • National Breast Cancer Awareness Month...

    A personal perspective from Dr Glynn Wilson, Chairman & CEO, TapImmune National Breast Cancer Awareness Month (NBCAM), We start October on a high note. On September 15, TapImmune and the Mayo...

    Read more

  • TapImmune Vaccine to be Studied in a $13.3 Million...

    Trial will Utilize Folate Receptor Alpha Vaccine Licensed to TapImmune for Commercialization JACKSONVILLE, Florida, September 15, 2015 /PRNewswire/ – TapImmune, Inc. (TPIV), congratulates...

    Read more

  • TapImmune Director to Represent Great Britain In T...

    TapImmune congratulates Director David Lasko-Pooley on being selected to represent Great Britain in the “2015 ITU World Triathlon Grand Final and World Championships to be held in Chicago, IL,...

    Read more

  • TapImmune Announces Finalization of License Agreem...

    Agreement Will Allow for the Transfer of IND from Mayo to TapImmune and the Initiation of Company-Sponsored Phase 2 Clinical Trials SEATTLE, July 27, 2015 /PRNewswire/ — TapImmune, Inc. (TPIV),...

    Read more

  • TapImmune Reports Robust Immune Responses Generate...

    Phase I Trial analyses shows safety and positive immune response data SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from...

    Read more

TapImmune to Present New Data at San Antonio Breast Cancer Symposium on December 10, 2015

JACKSONVILLE, Florida, December 7, 2015 /PRNewswire/

TapImmune (TPIV), a clinical-stage onco-immunology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today announced its Chairman and CEO, Dr. Glynn Wilson, will be presenting new data at the 2015 San Antonio Breast Cancer Symposium, which will be held in San Antonio, Texas on December 8 – 12, 2015.

Data will be presented at the poster session, “Treatment: Immunotherapy” on Thursday, December 10, from 7:30 am to 9:00 am. The poster titled, “Robust generation of T-cell immunity to HER2 in HER2+ breast cancer patients with a degenerate subdominant HLA-DR epitope vaccine,” was co-authored by Dr. Wilson, Dr. Knutson, Dr Degnim and other researchers from the Mayo Clinic in Rochester, MN.

The poster presentation will include previously unpublished data from a concluded Phase 1 trial conducted at the Mayo Clinic on a T-cell stimulating vaccine (TPIV 100) for the indication of HER2/neu breast cancer.  TapImmune has the Exclusive Option to license this technology from the Mayo Clinic.  The percent of patients that responded with augmented T cell immunity to the four peptide antigens contained in the vaccine was high for each peptide ranging from 68-88%, which led to the 90% of the patients augmenting T cells that recognized naturally processed HER2 antigen.  ”This presentation will present evidence of a robust and significant immune response using antigens designed to target HER2/neu epitopes known to be important targets in a variety of cancers. These are compelling data that has made us excited about initiating development efforts towards a Phase 2 program with this product” stated Dr. Wilson

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website athttp://www.tapimmune.com for details.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at http://www.sec.gov . The Company assumes no obligation to update the forward-looking statements.

Contacts:
TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1-866-359-7541

 

Life Sciences Intellectual Property Review

TapImmune featured in Life Sciences Intellectual Property Review

LSIPR logo
Page 1 of 212